Novel Technology Predicts Risk of Dementia
SAN FRANCISCO, CA, UNITED STATES, September 3, 2020 /EINPresswire.com/ — A novel technology has been shown to predict the risk of dementia 3 years ahead of onset. These findings provide a new opportunity for personalized preventive strategies.
A team of academic experts, from 24 global institutions, conducted this 40-month, multinational study across Europe and North America in memory clinics, general practitioner offices, and home environments. This study was done to validate the digital biomarker technology from ALTOIDA Inc, a brain health company. These findings were published, August 2020, in the journal: Alzheimer’s & Dementia Diagnosis, Assessment & Disease Monitoring.
Additional outcomes from this study include the ability to differentiate between people with, or without, amyloid brain pathology – and to predict a person’s rate of cognitive decline.
COVID pandemic and resulting brain health issues make this technology particularly valuable for a number of reasons. It allows consumers, families and care teams to remotely monitor cognitive function over time and track any decline. Harris Eyre MD PhD, of The PRODEO Institute states “Rates of cognitive decline in older adults are likely increasing due to a number of issues. COVID-related social and physical distancing creates more social isolation, a known risk factor for dementia. Emerging evidence indicates that the virus directly harms the brain. Finally, when a person requires ICU care and ventilator support, cognitive function is compromised because of stress, oxygen deprivation, systemic inflammation and multi-organ problems. This underscores the importance of better identification of at-risk individuals and the need to devote specialized brain health resources”.
Ioannis Tarnanas PhD, Founder and Chief Science Officer of ALTOIDA Inc, notes “ALTOIDA has the most precise identification of cognitive impairment and the early identification of an individual’s path toward cognitive impairment (e.g. Alzheimer’s Disease Dementias). Early identification is the trigger for prompt and effective mitigation. ALTOIDA’s scoring products and services enable an unmatched level of data acuity in making a quantifiable assessment of an individual’s cognitive and functional capabilities with ongoing monitoring and progression tracking.”
This peer-reviewed and published study validated ALTOIDA’s digital biomarker-based prognostic models. It characterized subjects using digital biomarkers in a longitudinal, multi-site, 40-month prospective study. A total of 496 individuals, either cognitively normal or diagnosed with Mild Cognitive Impairment, were involved in this study.
For further information, please contact ALTOIDA Inc at mark@altoida.com
Publication details
Buegler M et al (2020) Digital biomarker-based individualized prognosis for people at risk of dementia. Alzheimer’s & Dementia Diagnosis, Assessment & Disease Monitoring. Online. DOI: 10.1002/dad2.12073. https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/dad2.12073
About ALTOIDA Inc
ALTOIDA Inc is a brain health technology company with a proven technology offering the most precise identification of cognitive impairment and the early identification of an individual’s path toward cognitive impairment (e.g. Alzheimer’s disease and other dementias). Early identification is the trigger for prompt and effective mitigation. ALTOIDA’s scoring products and services enable an unmatched level of data acuity in making a quantifiable assessment of an individual’s cognitive and functional capabilities with ongoing monitoring and progression tracking. ALTOIDA’s products and services are backed by peer-reviewed publications, multinational clinical trials and an expert team of scientists, clinicians and informaticists. ALTOIDA Inc is funded by M-Ventures, Hikma Ventures, GreySky Venture Partners, FYRFLY, Alpana Ventures and VI Partners. For more on ALTOIDA, see https://altoida.com/
Mark Heinemeyer
ALTOIDA
+1 619-405-6500
email us here
Meet the global digital health ecosystem responding to the COVID-19 challenge and beyond.
Altoida’s FDA-cleared and CE Mark-approved medical device and brain health data platform detects Alzheimer’s Disease (AD) up to ten years prior to onset – with up to 94% accuracy.
Houston, TX – May 4, 2020 – Altoida Inc., a predictive digital biomarker company, today announced it has secured financing from Hikma Ventures, the venture capital arm of Hikma Pharmaceuticals PLC.
The financing comes at a time of rapid growth for Altoida, as the company’s -FDA cleared and CE Mark-approved medical device and brain health data platform is being used by researchers, patients and physicians across the globe to detect Alzheimer’s Disease (AD) up to ten years prior to onset. The additional financing will be used to further expand Altoida’s presence in the US, Japan, Europe and Brazil and follows the company’s $6.3 million Series A round that closed early 2019.
“Hikma Ventures is a highly reputable venture capital firm, and we share a common vision of putting better health within reach for millions of people across the globe,” said Dr. Richard Fischer, President & CEO of Altoida Inc. “Their investment in Altoida during these unprecedented times is a testament to their belief in the strength of our company and the value of our digital health technology. Hikma Ventures is the perfect addition to our investor syndicate and an important partner as we continue to execute on our clearly defined commercialization strategy.”
Altoida leverages predictive digital biomarkers to drive better clinical outcomes for brain disease. By leveraging the latest advancements in Artificial Intelligence (AI), Machine Learning (ML) and Augmented Reality (AR), Altoida collects functional and cognitive biomarkers to help detect Mild Cognitive Impairment (MCI) due to Alzheimer’s disease prior to its onset – with up to 94% accuracy. Now healthcare professionals have a novel way to objectively assess cognitive and everyday functions, in the most ecologically valid way.
Using Smart Device sensors, Altoida analyzes visuospatial and executive function during complex activities of daily living by asking patients to hide and seek virtual objects in a physical space. Altoida is able to detect “micro-errors” as both a prognostic and diagnostic digital biomarker, allowing medical professionals to detect Alzheimer’s disease in patients 62+ years old between six and ten years prior to the onset of symptoms – and before irreversible damage occurs. The company has validated its platform and methodology in more than 12 peer-reviewed journal publications and in more than 200 independent studies.
“We are excited to invest in Altoida and their digital health technology, which is helping patients and healthcare providers by reinventing digital biomarkers to drive better clinical outcomes for brain disease,” said Lana Ghanem, Managing Director of Hikma Ventures. “This is the latest example of Hikma Ventures commitment to supporting innovative companies utilizing machine learning and other cutting-edge technologies to meaningfully improve patients’ lives.”
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1/stable Moody’s and BB+/positive S&P)
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, the company has been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, Hikma is a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and they use their unique insight and expertise to transform cutting-edge science into innovative solutions that transform people’s lives. Hikma is committed to their customers, and the people they care for, and by thinking creatively and acting practically, they provide them with a broad range of branded and non-branded generic medicines. Together, Hikma’s 8,400 colleagues are helping to shape a healthier world that enriches all our communities. The company is a leading licensing partner, and through its venture capital arm, is helping bring innovative health technologies to people around the world. For more information, please visit hikma.com.
About Hikma Ventures
Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma’s expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company.
For more information, please visit hikmaventures.com.
About Altoida, Inc.
Altoida Inc. is a health technology firm that uses active digital biomarkers and cutting-edge technology in Artificial Intelligence (AI) and Augmented Reality (AR) to classify patients’ risk of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD) and drive better clinical outcomes for brain diseases. Led by an international team of esteemed neuroscientists, computer scientists and medical business professionals, the company offers an FDA-cleared and CE Mark-approved medical device and brain health data platform to support early detection of Alzheimer’s disease up to ten years prior to onset – with up to 94% accuracy. The company is privately held and supported by the current investor syndicate of M-Ventures (lead investor), GreySky Venture Partners, FYRFLY, Alpana Ventures, VI Partners. Altoida has offices in Houston, San Diego, and Lucerne, Switzerland. For more information, please visit altoida.com and follow us on LinkedIn linkedin.com/company/altoida.
Investor Enquiries
Hikma Ventures
Lana Ghanem
Managing Director, Hikma Ventures
lana@hikmaventures.com
+962 6 580 3100
Media Enquiries
Hikma Pharmaceuticals PLC
Steve Weiss
+1 732 720 2830/ +1 732 788 8279
David Belian
+1 732 720 2814/+1 848 254 4875
US Communications and Public Affairs
uscommunications@hikma.com
Altoida, Inc.
Emily Brady, BPR
emily@bradypr.com
+1 415 606 9350
HOUSTON, Jan. 14, 2020 /PRNewswire/ — Altoida, Inc. today announced that Chief Science Officer Ioannis Tarnanas has been selected to keynote at the upcoming Worldwebforum to share how Artificial Intelligence (AI), Augmented Reality (AR) and Active Digital Biomarkers (aDM) can be applied to the early detection of Alzheimer’s Disease. Tarnanas joins an elite group of leading academics and business innovators carefully chosen to present on how they are driving radical change and finding answers to future challenges.
Our CSO Dr. Ioannis Tarnanas who is a researcher in neurodegenerative diseases at ETH Zurich, explains how new technologies and apps can help Alzheimer’s patients and how they can be used as screening tools.
Next Generation Medicine at Hirslanden Kliniken Zurich, Switzerland